Abstract Number: 151 • 2020 Pediatric Rheumatology Symposium
Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes contain epigenetic marks associated with enhancer function…Abstract Number: 170 • 2020 Pediatric Rheumatology Symposium
Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE
Background/Purpose: The transition from pediatric to adult care for youth with chronic disease is known to be a vulnerable period, with adverse outcomes described for…Abstract Number: 176 • 2020 Pediatric Rheumatology Symposium
Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Research has established that a large percentage of individuals diagnosed with childhood-onset systemic lupus erythematosus (cSLE) report cognitive dysfunction. Disease factors that can impact…Abstract Number: 177 • 2020 Pediatric Rheumatology Symposium
Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
Background/Purpose: The literature regarding educational and socioeconomic outcomes in young adults with childhood-onset Systemic Lupus Erythematosus (cSLE) are sparse. cSLE patients recently transitioned to adult…Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…Abstract Number: 052 • 2020 Pediatric Rheumatology Symposium
Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls
Background/Purpose: Streptococcus pneumoniae (S. pneumoniae) may lead to severe life-threatening infections in both the general and immunocompromised population. Patients diagnosed with Systemic Lupus Erythematosus (SLE)…Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…Abstract Number: 75 • 2019 ACR/ARP Annual Meeting
Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. More than 50% of patients experience neuropsychiatric symptoms of…Abstract Number: 642 • 2019 ACR/ARP Annual Meeting
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Background/Purpose: Complement components, including C4d, can be detected on the surface of activated platelets and they have been associated with vascular disease in systemic lupus…Abstract Number: 703 • 2019 ACR/ARP Annual Meeting
Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune condition characterized by systemic inflammation that can exacerbate (flare) unpredictably, causing widespread organ damage. Identification of…Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 150
- Next Page »